Clinical Trial

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4), surufatinib and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-12
Trial Details
NCT Number NCT07103395
Lead Sponsor Sun Yat-sen University
Conditions Lung Cancer (NSCLC)
Enrollment 56 participants
Start Date 2026-01-01
Primary Completion 2029-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-14